###begin article-title 0
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Gastric cancer is the third most common malignancy affecting the general population worldwide. Aberrant activation of KRAS is a key factor in the development of many types of tumor, however, oncogenic mutations of KRAS are infrequent in gastric cancer. We have developed a novel quantitative method of analysis of DNA copy number, termed digital genome scanning (DGS), which is based on the enumeration of short restriction fragments, and does not involve PCR or hybridization. In the current study, we used DGS to survey copy-number alterations in gastric cancer cells.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
DGS of gastric cancer cell lines was performed using the sequences of 5000 to 15000 restriction fragments. We screened 20 gastric cancer cell lines and 86 primary gastric tumors for KRAS amplification by quantitative PCR, and investigated KRAS amplification at the DNA, mRNA and protein levels by mutational analysis, real-time PCR, immunoblot analysis, GTP-RAS pull-down assay and immunohistochemical analysis. The effect of KRAS knock-down on the activation of p44/42 MAP kinase and AKT and on cell growth were examined by immunoblot and colorimetric assay, respectively.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 548 553 548 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 669 673 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 796 801 796 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
DGS analysis of the HSC45 gastric cancer cell line revealed the amplification of a 500-kb region on chromosome 12p12.1, which contains the KRAS gene locus. Amplification of the KRAS locus was detected in 15% (3/20) of gastric cancer cell lines (8-18-fold amplification) and 4.7% (4/86) of primary gastric tumors (8-50-fold amplification). KRAS mutations were identified in two of the three cell lines in which KRAS was amplified, but were not detected in any of the primary tumors. Overexpression of KRAS protein correlated directly with increased KRAS copy number. The level of GTP-bound KRAS was elevated following serum stimulation in cells with amplified wild-type KRAS, but not in cells with amplified mutant KRAS. Knock-down of KRAS in gastric cancer cells that carried amplified wild-type KRAS resulted in the inhibition of cell growth and suppression of p44/42 MAP kinase and AKT activity.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 148 153 <span type="species:ncbi:9606">human</span>
Our study highlights the utility of DGS for identification of copy-number alterations. Using DGS, we identified KRAS as a gene that is amplified in human gastric cancer. We demonstrated that gene amplification likely forms the molecular basis of overactivation of KRAS in gastric cancer. Additional studies using a larger cohort of gastric cancer specimens are required to determine the diagnostic and therapeutic implications of KRAS amplification and overexpression.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KSAM</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MET </italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 237 240 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1075 1079 1075 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 1149 1150 1149 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Gastric cancer is the third most common malignancy affecting the general population worldwide [1]. Specific genetic changes have been reported in gastric cancer, including the amplifications of KSAM, MET and ERBB2, and mutations in p53, APC, and CDH1 [2]. While gain-of-function mutations of KRAS are some of the most commonly observed genetic alterations in a variety of tumors, including pancreatic (60%), biliary tract (33%) and colon (32%) [3], these mutations are infrequent in gastric cancer (2-7%) [4-7]. In general, RAS mutations associated with tumorigenesis "lock" RAS in an active GTP-bound state. GTP-RAS binds to a number of effector proteins to stimulate downstream signaling pathways, among which the RAF-MAP kinase cascade and the phosphatidylinositol 3-kinase (PI3K)-AKT pathways of cell growth and oncogenesis are the best characterized [3]. Prolonged activation of RAS can also occur through mechanisms that do not involve mutations in RAS. For example, reduced expression of let-7 microRNAs, which suppresses RAS by targeting the 3'untranslated region of RAS mRNAs, is often associated with a higher RAS protein level in tumors [8]. To date, the molecular mechanisms of oncogenic activation of RAS in gastric cancer have not been fully elucidated.
###end p 11
###begin p 12
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Amplification of genomic sequences containing genes that are critical for cell growth is one of the primary mechanisms of activation of oncogenes in cancer, and is often associated with tumor progression, poor prognosis and/or drug resistance [9]. Of the numerous methods currently available for detecting copy number alterations genome-wide, the current gold standard is the array CGH method (aCGH). Over the past few years, the resolution of aCGH has improved rapidly through the use of oligonucleotide probes, and has surpassed that of aCGH using standard BAC probes [10]. However, aCGH is also susceptible to the inherent noise of hybridization-based intensity measurements, as the signal quality is affected by repetitive sequences and is dependent on probe quality [11]. In fact, optimization of probe design has been a major challenge in the development of tiling arrays [12,13].
###end p 12
###begin p 13
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSF1 </italic>
###xml 460 464 460 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OTX2</italic>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MKK4 </italic>
###xml 491 502 491 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dystrophin </italic>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Digital karyotyping (DK) was developed by Wang et al. [14], and is not limited by the inherent problems of array techniques. DK involves the digital enumeration of short fragments of genomic DNA (termed tags), providing a quantitative measurement of DNA copy number through tag density analysis along each chromosome. DK has been applied successfully to a variety of tumor types to detect copy-number alterations, including the amplification of TYMS, RSF1 and OTX2, and deletion of MKK4 and dystrophin [15-19]. Despite the efficiency of DK, it is technically challenging for broad applications, because it involves PCR amplification and the generation of tags of 21-base pairs (bp) in length to precisely represent the chromosome location of interest.
###end p 13
###begin p 14
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
We report here the development of a novel method, termed DGS, for the quantitative analysis of copy number variation, which is based on the tag-counting concept of DK, but uses a simplified process of tag preparation. DGS of gastric cancer cell lines detected the amplification of the KRAS locus on chromosome 12p12.1. Our results provide a molecular basis for the overactivation of KRAS, and suggest that the activation of KRAS downstream signaling events may promote gastric cancer cell proliferation.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Cell lines and tissues
###end title 16
###begin p 17
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1178 1179 1178 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1295 1299 1295 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1577 1579 1577 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 515 519 <span type="species:ncbi:9913">calf</span>
###xml 671 678 <span type="species:ncbi:9606">patient</span>
The cell lines analyzed in the current study are listed in Additional file 1. The HSC and SH101P4 cell lines were established by Kazuyoshi Yanagihara [20]; all others were obtained from American Type Culture Collection or the Japanese Collection of Research Bioresources (Tokyo, Japan). All cell lines were cultured in the recommended media. For serum stimulation, cells were incubated in media that lacked serum for 24 hours (h), and then either unstimulated, or stimulated for 1 h with media containing 10% fetal calf serum (FCS). Primary gastric cancer specimens were obtained from the Department of Surgery, Keiyukai Sapporo Hospital, with informed consent from each patient. Genomic DNA was extracted using the phenol-chloroform method, followed by RNase treatment. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Genomic DNA of normal peripheral blood leukocytes (Biochain, Hayward, CA, USA) and total RNA from normal gastric mucosa from healthy individuals (Biochain and Invitrogen) were purchased. Primary gastric cancers were classified using clinicopathological features, as shown in Additional file 2, according to the pTNM classification scheme (5th edition, 1997) [21] and the Lauren's classification system [22]. KRAS-amplification status according to age was compared using the Student t test; according to grade, pT status, pN status, and disease stage using the Mann-Whitney U test; and according to gender, histology and pM status using the Fisher exact test. All tests were 2-tailed, and a P value of < 0.05 was considered statistically significant.
###end p 17
###begin title 18
Digital genome scanning
###end title 18
###begin p 19
###xml 84 87 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 280 283 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 390 407 389 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 594 597 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spe</italic>
###xml 599 602 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 830 833 829 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spe</italic>
###xml 835 838 834 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 1423 1425 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1426 1428 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1496 1506 1495 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 1551 1552 1550 1551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 390 406 <span type="species:ncbi:562">Escherichia coli</span>
###xml 1017 1022 <span type="species:ncbi:9606">human</span>
Briefly, 40 mug of genomic DNA were subjected to restriction enzyme digestion using MboI (Takara, Tokyo, Japan) and then separated by electrophoresis on a 3% Nusieve GTG agarose gel. Short fragments (30-60 bp, termed real tags) were electroeluted, concatenated and subcloned into BamHI-digested pBluescript II KS+ (Stratagene, La Jolla, CA) using Mighty Mix DNA ligation solution (Takara). Escherichia coli DH10B were transformed with the recombinant plasmids, the transformants were pooled and the plasmid DNA was purified to generate the 1st library. Concatemers of real tags were excised by SpeI/PstI digestion from the 1st library, and fragments in the range of 140 to 800 bp were electroeluted, concatenated and subcloned into pBluescript II KS+ to generate the 2nd library. Second library plasmids containing concatemers of SpeI/PstI fragments were sequenced using an ABI3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), according to manufacturer's instructions. Unique real tags were mapped to human chromosome sequences, and tag density, defined as the ratio of real tags to virtual tags over moving windows, was calculated to detect abnormalities in DNA content using threshold values defined by DGS simulations. Tag positions and tag density ratios were visualized using Custom Tracks and Genome Graphs from the University of California, Santa Cruz (UCSC) genome browser (Mar. 2006 freeze, hg18) [23-25]. The detailed protocols for DGS, virtual tag characterization and in silico simulations are available in Additional file 3.
###end p 19
###begin title 20
Quantitative real-time PCR
###end title 20
###begin p 21
###xml 360 363 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nt </italic>
###xml 365 370 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nline</italic>
###xml 373 376 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xt </italic>
###xml 378 383 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xline</italic>
###xml 359 384 351 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(<italic>Nt </italic>- <italic>Nline</italic>)-(<italic>Xt </italic>- <italic>Xline</italic>)</sup>
###xml 392 393 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 393 395 385 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 393 395 385 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>t </italic></sub>
###xml 486 487 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 487 492 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line </italic>
###xml 487 492 479 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>line </italic></sub>
###xml 578 581 570 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xt </italic>
###xml 680 681 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 681 686 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line </italic>
###xml 681 686 673 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>line </italic></sub>
###xml 775 777 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 933 934 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 969 974 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1077 1083 1067 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 1084 1086 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1143 1144 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 1426 1432 1416 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1514 1515 1504 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
Relative DNA copy number was determined by quantitative real-time PCR using a SYBR Green PCR Master Mix (Applied Biosystems) and the ABI PRISM 7000 (Applied Biosystems). DNA content per haploid genome was normalized to that of a repetitive element, Line-1, and calculated by the comparative CT (DeltaDeltaCT) relative quantification method using the formula 2(Nt - Nline)-(Xt - Xline), where Nt is the threshold cycle number observed for an experimental primer in normal leukocyte DNA, Nline is the threshold cycle number observed for the Line-1 primer in normal leukocyte DNA, Xt is the average threshold cycle number observed for the experimental primer in cancer cell DNA, and Xline is the average threshold cycle number observed for the Line-1 primer in cancer cell DNA [14]. Genomic amplification was defined as a greater than 4-fold increase in DNA content. The primer sequences for each locus are available in Additional file 4. The allelic proportion of mutant KRAS (G12V, ggt-->gTt) was determined by employing a modified real-time PCR procedure according to Itabashi et al [26]. The detailed protocol is available in Additional file 3. cDNA was prepared using SuperScript III reverse transcriptase (RT, Invitrogen), and the mRNA level of each gene was determined by real-time RT-PCR using the TaqMan Gene Expression Assay (Applied Biosystems). Relative mRNA levels were calculated by the comparative CT method using GAPDH as an endogenous control. The primer/probe sets used are shown in Additional file 5.
###end p 21
###begin title 22
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Fluorescence in situ hybridization (FISH)
###end title 22
###begin p 23
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
BACs that contained the KRAS locus (RP11-636P12) and chromosome 12q24.2 (RP11-91M21) were labeled with Cy3 and Cy5, respectively, and then incubated with slides prepared with interphase and metaphase chromosomes. Nuclei were counter-stained with 4',6-diamino-2-phenylindole (DAPI), and slides were analyzed using a fluorescence microscope (Leica CW-4000).
###end p 23
###begin title 24
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
Mutational analysis of KRAS and PIK3CA
###end title 24
###begin p 25
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 345 352 345 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
Amplified genomic fragments were either sequenced directly, or subcloned using the TOPO TA-cloning kit (Invitrogen) and then sequenced. At least ten clones from two independent PCR assays per locus were sequenced using M13 Forward and Reverse primers (Invitrogen). The sequences of the primers used for amplification of KRAS (exons 1 and 2) and PIK3CA (exons 9 and 20) are shown in Additional file 6.
###end p 25
###begin title 26
Immunoblot analysis
###end title 26
###begin p 27
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 689 695 <span type="species:ncbi:9986">rabbit</span>
Cells were lysed in Lysis buffer containing 20 mM Tris-HCl (pH7.5) buffer, 150 mM NaCl, 1 mM EDTA, 1% Triton X, 10% glycerol, 10 mM NaF, 1 mM sodium vanadate, 50 mM beta-glycerophosphate, 1 mM phenylmethansulfonyl fluoride, 1 mM dithiothreitol, and a protease inhibitor cocktail (Roche, Mannheim, Germany). Proteins were separated by SDS-PAGE and electroblotted onto an Immobilon-P membrane (Millipore, Billerica, MA, USA). The membranes were analyzed by immunoblot using the following antibodies, as indicated: mouse monoclonal anti-KRAS, -NRAS, and -HRAS antibodies (sc-30, sc-31, and sc-29, respectively, Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-actin antibody (Millipore); rabbit polyclonal anti-p44/42 MAP kinase, -phosho-p44/42 MAP kinase (Thr202/Tyr204), -Akt and -phospho-Akt (Ser473) antisera (Cell Signaling Technology, Danvers, MA, USA).
###end p 27
###begin title 28
GTP-RAS pull-down assay
###end title 28
###begin p 29
The activation of RAS was detected using an EZ-Detect Ras Activation Kit (Pierce, Rockford, IL, USA). Briefly, cell lysate (500 mug) was incubated with immobilized Raf1 Ras-binding domain fused to glutathione S-transferase (GST-Raf1-RBD). Precipitates were washed 3 times, and bound proteins were eluted by boiling for 5 minutes (min). Proteins were resolved on a 12% polyacrylamide gel, transferred to an Immobilon-P membrane, and subjected to immunoblot analysis using anti-KRAS, -NRAS, or -HRAS antibodies.
###end p 29
###begin title 30
RNA interference
###end title 30
###begin p 31
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRMP</italic>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5 </italic>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASC1 </italic>
###xml 421 423 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
A custom-designed KRAS siRNA (5'-AGAGUGCCUUGACGAUACAdTdT-3'), targeting a region of KRAS that is not associated with known oncogenic mutations, was synthesized by Dharmacon (Lafayette, Co, USA). siRNAs targeting LRMP, LYRM5 and CASC1 were purchased from Ambion (No.144181, 284911 and 147715). A universal non-targeting siRNA (non-specific control VII, Dharmacon) was used as a negative control. In each experiment, 5 x 106 cells were transfected with 7.5 mul of 20 muM siRNA by electroporation (Amaxa, Cologne, Germany) using Nucleofector kit V or T, according to the manufacturer's instructions.
###end p 31
###begin title 32
Cell proliferation assay
###end title 32
###begin p 33
Following transfection with siRNAs, the gastric cancer cell lines HSC45, MKN1, AGS and NUGC4 were seeded in 96-well plates at a density of 8000 cells/100 mul in standard medium containing 10% FCS. Cell number at 48, 72 and 96 h post-transfection was determined indirectly by colorimetric assay using Cell Counting Kit-8 solution (Dojindo, Kumamoto, Japan). The assay is based on the reduction of a tetrazolium salt ([2-(2-methoxy-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2-tetrazolium, monosodium salt], WST-8) and is used as a measure of live cells. The absorbance of each well at 450 nm was measured using a microplate reader (Model 680, Bio-Rad, Hercules, CA, USA).
###end p 33
###begin title 34
Flow cytometry
###end title 34
###begin p 35
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Flow cytometry was carried out as described previously [27]. Briefly, adherent and detached cells were harvested, fixed in 90% cold ethanol, treated with RNase A (500 units/ml), and then stained with propidium iodide (50 mug/ml). For each sample, 30000 events were analyzed using the cell cycle analysis platform of FlowJo program (Tree Star, Ashland, OR, USA).
###end p 35
###begin title 36
Immunohistochemistry
###end title 36
###begin p 37
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 150 152 150 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
Formalin-fixed, paraffin-embedded sections of gastric tumors were deparaffinized, hydrated, and then treated with peroxidase blocking solution (3% H2O2 in Methanol). Sections were autoclaved at 105degreesC for 10 min in target retrieval solution (Dako, Glostrup, Denmark). Sections were incubated with a mouse anti-KRAS antibody (1:100 dilution; Santa Cruz Biotechnology) for 1 h at room temperature, and immunoreactivity was detected using ENVISION-Plus reagents (Dako).
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
###xml 61 70 61 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
Digital genome scanning and characterization of virtual tags in silico
###end title 39
###begin p 40
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 445 455 445 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In silico </italic>
###xml 488 491 488 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 615 616 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 986 987 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 1308 1309 1308 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 1608 1609 1608 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 1717 1718 1717 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 1728 1738 1728 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 1784 1787 1784 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 472 477 <span type="species:ncbi:9606">human</span>
###xml 846 851 <span type="species:ncbi:9606">human</span>
Digital genome scanning (DGS) is a method of quantitating gene copy number by enumerating short genomic DNA fragments (termed real tags) that are generated experimentally by MboI endonuclease digestion (Figure 1a). To eliminate the complicated steps involved in tag preparation, we computationally characterized the short DNA fragments that are produced by single restriction enzyme digestion with MboI, which recognizes the 4-bp sequence GATC. In silico digestion of the human genome by MboI produced approximately 1.6 million restriction fragments (termed virtual tags) in the range of 20-130 bp (Additional file 7a). Nucleotide sequence analysis revealed that approximately 65% of the virtual tags contained repetitive sequences, as defined in the public database of repeat elements (Additional file 7a). Importantly, sequence matching to the human genome database revealed that approximately 85% of the virtual tags mapped uniquely to precise chromosomal locations (Additional file 7b, c). Even if the virtual tags include repetitive sequences in part, approximately 80% of the repetitive tags turned out to be unique. The average distance between two unique virtual tags of 30 to 60 bp in length was 7.6 kb, the median distance was 4.5 kb and 97.8% of intervals were shorter than 30 kb (Additional file 7d). Similar tag interval characteristics were observed for virtual tags the range of 70 to 100 bp (average distance, 7.9 kb; median distance, 4.8 kb; 97.4% were shorter than 30 kb), and 100 to 130 bp (average distance, 7.9 kb; median distance, 4.9 kb; 97.4% were shorter than 30 kb (Additional file 7e, f). Furthermore, the density of unique virtual tags was nearly equal in each chromosome (Additional file 7g). These in silico findings suggested that the majority of short MboI tags would be informative for DGS.
###end p 40
###begin p 41
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DGS and preparation of real tags</bold>
###xml 35 36 35 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 135 137 135 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 141 142 141 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 157 158 157 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 283 284 283 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 305 308 305 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 787 790 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 792 795 792 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 857 860 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spe</italic>
###xml 862 865 862 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 923 924 923 924 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
DGS and preparation of real tags. (a) Schematic outline of DGS. Colored boxes represent genomic MboI real tags. See text for details. (b and c) Preparation (b) and characterization (c) of real tags. Representative results using genomic DNA from MKN1 gastric cancer cells are shown. (b) Short fragments of MboI-digested genomic DNA (30 to 60 bp) were electroeluted from an agarose gel (i), concatenated and subcloned. Resultant recombinant plasmids were pooled to generate the 1st library (ii). Long concatemers (140 to 800 bp) were excised from 1st library vectors, electroeluted (iii), concatenated and subcloned. The resultant recombinant plasmids represent 2nd library clones (iv). The number of tags contained in each clone is shown at the top of each lane. Inserts were examined by XhoI/SacI digestion in panels (ii) and (iv). *, vector fragments; **, SpeI/PstI digestion of the multiple-cloning site without insert. (c) Actual number of real tags from the 2nd library is shown in the histogram (left), and their characteristics are summarized (right).
###end p 41
###begin title 42
###xml 15 24 15 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
DGS simulation in silico
###end title 42
###begin p 43
###xml 746 747 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 396 399 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
The ability of DGS to detect genome-wide changes is based on genome characteristics, such as the copy number and the size of the alteration, and the number of real tags obtained from sequence analysis. To predict the size of alteration that could reliably be detected, given a fixed number of computationally sampled tags, we used Monte Carlo simulation to calculate a positive predictive value (PPV), which is the probability that a detected alteration represents a true alteration. For example, we found that an analysis of 5000 tags could reliably detect a 10-fold amplification of 500 kb, a homozygous deletion of 7.5 Mb, or a single copy loss of a 30 Mb region, but could not detect a subchromosomal gain smaller than 30 Mb (Additional file 8). Both the sensitivity and specificity of detecting these types of alteration were >99% in cases with high PPVs (>90%), which indicated that neither was a limiting factor in this analysis (data not shown).
###end p 43
###begin title 44
###xml 30 35 <span type="species:ncbi:9606">human</span>
Preparation of real tags from human genomic DNA
###end title 44
###begin p 45
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 137 140 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
For DGS of the gastric cancer cell lines HSC45 and MKN1, we prepared libraries of real tags from genomic DNA, as shown in Figure 1a. The MboI-digested genomic DNA was size-fractionated (30-60 bp) and subjected to concatemerization, followed by construction of a 2nd library, which contained approximately 10 real tags per clone (Figure 1b). Nucleotide sequence analysis of the real tags revealed that 85.8% mapped to unique positions, which was consistent with our characterization of virtual tags (Figure 1c).
###end p 45
###begin title 46
Amplifications on chromosome 12p in HSC45 gastric cancer cells
###end title 46
###begin p 47
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 824 828 824 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 830 838 830 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CACNA1C </italic>
###xml 905 909 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 967 972 967 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 976 980 976 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1027 1028 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 1290 1291 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 1413 1418 <span type="species:ncbi:9606">human</span>
The genome-wide tag density profile of HSC45 cells was determined using a total of 5,462 unique real tags. To achieve high resolution and sensitivity with the experimental data, we used window sizes of 1000 and 2100 virtual tags (approximately 2300 kb and 4700 kb) for the analysis of amplifications and deletions, respectively. The tag density ratio was calculated as the sum of real tags divided by the average number of real tags in same-sized windows throughout the genome, in which the normal tag density ratio was defined as 1.0. We identified distinct subchromosomal regions of increased tag density at 8q24.21, 12p12.1 and 12p13.33, and decreased tag density at 9p21.3 and the long arm of chromosome 18 (Figure 2, Additional file 9a-d). The regions of increased tag density (12p12.1, 12p13.33 and 8q24.21) contained KRAS, CACNA1C (calcium channel, voltage-dependent, l type, alpha-1c subunit) and MYC loci, respectively. Southern blot analysis confirmed that KRAS and MYC were amplified in HSC45 cells (Additional file 9e). Each quantitated copy-number change as determined from quantitative real-time PCR (qPCR) of genomic DNA was remarkably similar to that estimated by DGS when the window size for tag density analysis was matched to the size of each alteration (Additional file 9a-d). These results suggest that tag density analysis by DGS could be used to perform copy number analysis throughout the human genome.
###end p 47
###begin p 48
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of increased copy number on chromosomes 8q and 12p by DGS in HSC45 gastric cancer cells</bold>
###xml 100 101 100 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 438 440 438 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 444 445 444 445 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 501 502 501 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 512 513 512 513 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
Detection of increased copy number on chromosomes 8q and 12p by DGS in HSC45 gastric cancer cells. (a) A whole-genome view of the tag density ratio (using a window of 1000 virtual tags) in HSC45 cells as determined by DGS. Values on the y-axis indicate fold-changes in tag density relative to the average tag density of the whole genome, and represent DNA content per haploid genome, in windows. The x-axis represents chromosome number. (b and c) Expanded view of tag density ratios on chromosomes 8 (b) and 12 (c). In each panel, the upper graph shows a whole-chromosome view of the tag density ratio (based on a window of 1000 virtual tags). The lower graph shows an expanded view of 8q24.21 and 12p12.1, in which increased tag density was detected using windows of 1000 and 500 virtual tags. Unique real tags are indicated as black vertical bars, and unique virtual tags are indicated in blue (60 bp or shorter) or light blue (longer than 60 bp) bars in dense mode. The positions of refseq genes, with some splicing isoforms omitted, are shown at the bottom of the lower panels.
###end p 48
###begin title 49
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Amplification of KRAS in gastric cancer cell lines
###end title 49
###begin p 50
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S10">10</xref>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRMP </italic>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASC1 </italic>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5 </italic>
###xml 852 858 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAT1 </italic>
###xml 993 1001 993 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CACNA1C </italic>
###xml 1145 1146 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 1174 1178 1174 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRAS</italic>
###xml 1180 1185 1180 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HRAS </italic>
###xml 1189 1194 1189 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 1318 1323 1318 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1383 1388 1383 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1484 1486 1484 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
Analysis of 26 loci within and immediately flanking chromosome 12p12.1 in HSC45 cells by qPCR demonstrated that a region of approximately 500 kb, which included the KRAS gene locus, was amplified (8-fold amplification, Figure 3a). Genomic qPCR screening detected KRAS amplification in two additional gastric cancer cell lines, SH101P4 (18-fold) and MKN1 (13-fold) (Figure 3a), whereas we did not detect amplification of greater than 4-fold in 17 other gastric cancer cell lines, or in 10 colon cancer and 11 pancreatic cancer cell lines (listed in Additional file 1, data not shown). DGS also detected amplification of the KRAS locus in MKN1 cells (Additional file 10). The neighboring genes of KRAS in the minimal amplicon were LRMP (lymphoid-restricted membrane protein), CASC1 (cancer susceptibility candidate 1) and LYRM5 (LYR motif containing 5). BCAT1 (branched chain aminotransferase 1, cytosolic) was also amplified in SH101P4 and MKN1 cells, but not in HSC45 cells. We confirmed that CACNA1C was amplified in HSC45 cells, but not in the other gastric, colon, or pancreatic cancer cell lines using genomic qPCR analysis (Additional file 9b; data not shown). Neither NRAS, HRAS nor BRAF amplifications were detected in the above cancer cell lines by genomic qPCR analysis (data not shown). The amplification of KRAS was also verified by dual color FISH analysis, in which the KRAS amplicon was evident as a homogeneously-stained region in HSC45, SH101P4 and MKN1 cells (Figure 3b).
###end p 50
###begin p 51
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene amplification of <italic>KRAS </italic>in gastric cancer cells</bold>
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 579 580 579 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 654 659 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 888 889 888 889 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 933 938 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1036 1054 1036 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS, LRMP, CASC1 </italic>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5</italic>
###xml 1106 1111 1106 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAT1</italic>
###xml 1223 1229 1223 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1364 1369 1364 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1494 1498 1494 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1561 1565 1561 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
Gene amplification of KRAS in gastric cancer cells. (a) Quantitative genomic PCR analysis of the KRAS locus at 12p12.1 in HSC45 cells. Discrete amplifications at 12p12.1 in two other gastric cancer cell lines were also detected (SH101P4 and MKN1). DNA copy number relative to normal diploid leukocyte DNA was plotted against chromosomal nucleotide position (in megabases). The positions of refseq genes in the corresponding regions are shown in the bottom map. The minimum amplification region common to all 3 gastric cancer cell lines is represented by the orange-colored bar. (b) Metaphase (left)- and interphase (right)-FISH analysis of the amplified KRAS locus in gastric cancer cell lines. The KRAS-specific probe is in yellow, and the control probe, specific for the long arm of chromosome 12, is in red. Tetraploidy in HSC45 and triploidy in SH101P4 and MKN1 cells were observed. (c) Quantitative real-time RT-PCR analysis of KRAS mRNA expression in gastric cancer cells with 12p12.1 amplification. Expression analysis of genes (KRAS, LRMP, CASC1 and LYRM5) located within the minimal amplicon, and BCAT1, which flanks the minimal amplicon, was performed using real-time RT-PCR. Expression levels were normalized to GAPDH mRNA, and are depicted as a color gradient, relative to normal stomach. The gene amplification and mutation (codon 12 or 13) status of KRAS for each sample is summarized in the right two columns. Filled circles indicate the presence of amplification or mutation of KRAS, and open circles indicate no amplification or no mutation of KRAS.
###end p 51
###begin p 52
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S11">11</xref>
###xml 224 229 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 256 261 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 365 367 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 368 370 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 398 403 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 639 644 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 669 671 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S11">11</xref>
###xml 861 866 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Sequence analysis of KRAS (Additional file 11a) showed that both HSC45 and SH101P4 cells harbored a mutation in codon 12 that resulted in a single amino acid substitution in KRAS (ggt-->gTt, G12V), whereas MKN1 cells lacked KRAS mutations. The presence of KRAS mutations in AGS (G12D), SNU1 (G12D), DLD1 (G13D) and HCT116 (G13D) cells has been reported previously [28,29]. Of the ten PCR-clones of KRAS from HSC45 and SH101P4 cells that were subjected to mutational analysis, eight and three, respectively, harbored mutations in codon 12. Furthermore, genomic real-time PCR analysis using probes that were specific to wild-type and mutant KRAS alleles (Additional file 11b) also revealed that HSC45 and SH101P4 cells contain different proportions of the mutant allele (80% and 50%, respectively). Overall, these results indicated that amplification of a mutant KRAS allele also occurs in HSC45 and SH101P4 cells.
###end p 52
###begin p 53
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5 </italic>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASC1</italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRMP </italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 850 851 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S12">12</xref>
###xml 1077 1081 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
We next investigated the levels of KRAS mRNA in KRAS-amplified gastric cancer cells by quantitative real-time RT-PCR (qRT-PCR) (Figure 3c). The levels of KRAS mRNA correlated significantly with KRAS copy number. The neighboring genes LYRM5 and CASC1, which localized to the minimal amplicon, were also expressed at higher levels in cells with amplification as compared to cells without amplification (Figure 3c). Interestingly, LRMP was down-regulated in cancer cells as compared to normal stomach cells. Immunoblot analysis of RAS proteins (Figure 4a) revealed that the expression of KRAS was increased in KRAS-amplified gastric cancer cells (HSC45, SH101P4 and MKN1), while neither NRAS nor HRAS were highly expressed (Figure 4a; data not shown). Although the expression of let-7c and let-7g microRNAs has been reported to regulate RAS expression [8], we found little correlation of expression of these microRNAs with KRAS protein levels (Additional file 12), which suggested that KRAS overexpression in gastric cancer cell lines is due primarily to genomic amplification of KRAS.
###end p 53
###begin p 54
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 0 125 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of KRAS, and differential activation of KRAS, p44/42 MAP kinase and AKT in <italic>KRAS</italic>-amplified gastric cancer cells</bold>
###xml 128 129 128 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 263 264 263 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 678 679 676 677 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 954 955 952 953 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1106 1107 1104 1105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1300 1305 1298 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Overexpression of KRAS, and differential activation of KRAS, p44/42 MAP kinase and AKT in KRAS-amplified gastric cancer cells. (a) Immunoblot analysis of the expression levels of KRAS and NRAS in cancer cells. Actin expression was analyzed as a loading control. (b) The basal level of GTP-KRAS was markedly high in gastric cancer cells with amplified mutant KRAS (HSC45 and SH101P4). Total lysate (500 mug) was subjected to a GTP-RAS pull-down assay, and GTP-KRAS and GTP-NRAS were detected by immunoblot using anti-KRAS and anti-NRAS antibodies, respectively. Total cell lysate (50 mug) was analyzed in parallel to determine the level of expression of KRAS and NRAS in cells. (c) GTP-KRAS was elevated after serum stimulation in MKN1 cells. Cells were cultured in regular medium containing 10% FCS (N), serum-starved for 24 h (-) or serum-starved then stimulated with 10% FCS for 1 h (+). Total cell lysate was subjected to a GTP-KRAS pull-down assay. (d) Activation of p44/42 MAP kinase and AKT in serum-starved or -stimulated gastric cancer cells. Total cell lysate was analyzed as described for figure c. The phosphorylation of p44/42 MAP kinase and AKT was detected by immunoblot using anti-phospho-specific antibodies. In each panel, the status of gene amplification and mutation (codon 12) of KRAS in each cell line is indicated. +, presence; -, absence.
###end p 54
###begin title 55
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
Activation of downstream signaling in KRAS-amplified gastric cancer cells
###end title 55
###begin p 56
###xml 107 116 107 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
To investigate KRAS activity in gastric cancer cells, we analyzed the amount of GTP-KRAS in cells using an in vitro pull-down assay. There was a higher amount of GTP-KRAS in HSC45 and SH101P4 cells, which carried amplified mutant KRAS, than in MKN1 cells, in which the level of GTP-KRAS was comparable to AGS cells, which carried non-amplified mutant KRAS (Figure 4b). Serum stimulation had little effect on the level of GTP-KRAS in HSC45 cells, but resulted in a dramatic elevation of GTP-KRAS in MKN1 cells (Figure 4c). As expected, this data was consistent with constitutively active mutant KRAS overexpression due to amplification, and it suggested that overexpression of wild-type KRAS may also promote oncogenic properties when cells are exposed to external stimuli.
###end p 56
###begin p 57
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 388 392 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
To gain further insight into the role of overexpressed KRAS in cancer cell growth, we analyzed the activation of p44/42 MAP kinase and AKT (Figure 4d), which are pivotal molecules in the MAP kinase cascade and PI3K signaling pathways that are downstream of KRAS [3,30]. Under normal culture conditions (Figure 4d, lanes indicated as "N"), basal phosphorylation of p44/42 was increased in KRAS-amplified cells (HSC45, MKN1, and SH101P4) as compared to NUGC4 gastric cancer cells, in which there is neither amplification nor mutation of KRAS. While the phosphorylation of p44/42 was modestly increased in MKN1 cells after serum stimulation, the effect of serum stimulation on HSC45 and SH101P4 cells was minimal, which indicated that p44/42 is constitutively active in the latter two cell lines.
###end p 57
###begin p 58
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S13">13</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 571 576 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 710 715 710 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a, b</xref>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 839 844 839 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
To investigate the biological significance of KRAS amplification in gastric cancer, we used small interfering RNA (siRNA) to knock-down the expression of KRAS or KRAS neighboring genes in four gastric cancer cell lines, HSC45 (carrying amplification and mutation of KRAS), MKN1 (amplification but no mutation of KRAS), AGS (mutation but no amplification of KRAS) and NUGC4 (no amplification or mutation of KRAS). Knock-down of KRAS and three neighboring genes was verified by qRT-PCR (Additional file 13) and KRAS immunoblot analysis (Figure 5a). While the knock-down of KRAS in HSC45 and MKN1 cells caused a marked reduction in phosphorylation of p44/42, knock-down of neighboring genes had no effect (Figure 5a, b). Phosphorylation of p44/42 was reduced in KRAS knock-down AGS cells, but not in NUGC4 cells. These results indicated that KRAS amplification is associated with both transient and constitutive activation of p44/42 MAP kinase.
###end p 58
###begin p 59
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 0 127 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Suppression of downstream signaling and cell growth in <italic>KRAS</italic>-amplified gastric cancer cells by siRNA-mediated knock-down of <italic>KRAS</italic></bold>
###xml 173 191 173 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS, LRMP, CASC1 </italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5</italic>
###xml 250 251 250 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 607 608 607 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1016 1017 1016 1017 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1049 1053 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1073 1078 1073 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1491 1493 1491 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1583 1584 1583 1584 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1586 1591 1586 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Suppression of downstream signaling and cell growth in KRAS-amplified gastric cancer cells by siRNA-mediated knock-down of KRAS. Cells were transfected with siRNA targeting KRAS, LRMP, CASC1 or LYRM5, or a non-targeting siRNA as a negative control. (a) KRAS knock-down suppressed the phosphorylation of p44/42 in KRAS-amplified cells. Protein levels of KRAS and activated p44/42 48 h post-transfection were determined by immunoblot using anti-KRAS and anti-phospho-p44/42 antibodies. The status of gene amplification and mutation (codon 12) of KRAS in each cell line is indicated. +, presence; -, absence. (b) KRAS knock-down suppressed the phosphorylation of p44/42 MAP kinase and AKT in MKN1 cells. Twenty-four h after siRNA transfection, MKN1 cells were cultured for an additional 24 h in regular medium (Nontreated), serum-starved for 24 h (Starved) or serum-starved then stimulated with 10% FCS for 1 h (+Serum). The activation of p44/42 and AKT was determined by immunoblot using phospho-specific antibodies. (c) Suppression of cell growth in KRAS-amplified cells by KRAS knock-down. Cells were transfected with siRNA, and cell number at the indicated time points after transfection was determined indirectly by WST-8 colorimetric assay. Data is presented as percent decrease in cell number as compared to cells transfected with control siRNA at each time point, and represents the means and SD for triplicate cultures. Statistical analysis was performed using the unpaired t-test. *, P < 0.005 relative to the siRNA control. Data is representative of two independent assays. (d) KRAS knock-down decreased the fraction of HSC45 and AGS cells in S-phase. Cells were analyzed by flow cytometry 48 h post-transfection. Data is representative of two independent assays.
###end p 59
###begin p 60
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 235 242 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S11">11</xref>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
Basal phosphorylation of AKT was detected under normal culture conditions, and was increased after serum stimulation of MKN1 and AGS cells (Figure 4d). Nucleotide sequence analysis revealed a single nucleotide mutation at codon 545 of PIK3CA in MKN1 and AGS cells (E545K and E545A, respectively, Additional file 11c), which suggested that AKT is potentially activated in these cells through mutational activation of PIK3CA. However, in MKN1 cells, phosphorylation of AKT was reduced by KRAS knock-down under both the normal culture condition as well as after serum stimulation (Figure 5b), which suggested that the overexpression of wild-type KRAS might also be involved in enhancing the activation of AKT.
###end p 60
###begin title 61
Growth inhibition of gastric cancer cells with amplification at 12p12.1 by the downregulation of KRAS
###end title 61
###begin p 62
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 399 404 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 595 600 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 702 707 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 837 842 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Among the four genes that localized to the minimal amplicon at 12p12.1, the knock-down of KRAS caused a significant inhibition of cell growth in HSC45, MKN1 and AGS cells (Figure 5c, P < 0.005, t-test), whereas knock-down of the other three genes had no effect. There was little growth inhibition observed in NUGC4 cells, in which KRAS is neither amplified nor mutated. These results suggested that KRAS is the driver gene responsible for the promotion of proliferation of cancer cells harboring 12p12.1 amplification, and the other three genes are likely to be passenger genes on the amplicon. KRAS knock-down HSC45 and AGS cells exhibited a reduced accumulation of S-phase cells (Figure 5d), whereas KRAS knock-down had no effect on S-phase accumulation in MKN1 cells. Taken together, these results suggested that the amplification of KRAS is involved in the promotion of cancer cell growth through the activation of the p44/42 MAP kinase pathway, and in part through activation of the AKT pathway.
###end p 62
###begin title 63
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Amplification of wild-type KRAS in primary gastric cancer
###end title 63
###begin p 64
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 330 337 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
To determine the role of KRAS in primary gastric cancer, we used qPCR to analyze KRAS amplification in genomic DNA derived from primary gastric cancer specimens. We screened 86 specimens, and found amplification of the KRAS locus (8-50-fold) in four of them (4.7%) (Figure 6a). Furthermore, mutations were not detected in KRAS or PIK3CA (exon 9 and 20) in these four tumors by nucleotide sequencing analysis of the PCR products or clones of the PCR products (data not shown). With the exception of tumor C, histopathology of the tumors indicated that they were generally of the diffuse-type, according to the Lauren's classification system [22], and there were no significant differences in clinicopathological features between KRAS-amplification-positive and -negative tumors (Additional file 2). Immunohistochemical analysis specifically detected KRAS in cancer cells (tumor D, Figure 6b), whereas the expression of KRAS in adjacent noncancerous cells was below the level of detection. Gene amplification coincided with intense KRAS immunoreactivity in the same tumor samples, which suggested that gene amplification results in the overexpression of the KRAS in primary gastric cancer.
###end p 64
###begin p 65
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amplification of <italic>KRAS </italic>in primary gastric cancer</bold>
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 357 358 357 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Amplification of KRAS in primary gastric cancer. (a) Quantitative PCR analysis of genomic DNA from primary gastric cancer specimens was carried out using primers specific for regions within and flanking the KRAS locus. DNA copy number relative to normal diploid leukocyte DNA is plotted onto the corresponding chromosomal nucleotide position in megabases. (b) KRAS is preferentially expressed in gastric cancer cells with KRAS amplification. Hematoxylin-Eosin staining (left) and immunohistochemical staining with an anti-KRAS antibody (right) of gastric cancer tissue (tumor D). Upper panels: poorly-differentiated adenocarcinoma cells with submucosal invasion. Lower panels: adenocarcinoma cells adjacent to normal pyloric glands.
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 593 601 593 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CACNA1C </italic>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 101 106 <span type="species:ncbi:9606">human</span>
In this report, we described a novel method, termed DGS, of detecting copy number alterations in the human genome, which is based on the analysis of short fragments of genomic DNA generated by restriction enzyme digestion. Although DGS is modeled on the basic concept of DK, we developed a modified tag preparation technique that involves single restriction enzyme digestion without PCR to minimize complex handling regimes and potential biases generated by PCR. Our relatively small-scale sequencing of approximately 5000 tags successfully detected discrete 500-kb amplifications of KRAS and CACNA1C in HSC45 cells, which were not previously reported in an independent experiment using BAC-based aCGH analysis [31].
###end p 67
###begin p 68
###xml 133 136 133 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
To date, however, this DGS method has some limitations as compared to DK and other methods. First, the resolution of DGS using short MboI tags is lower than DK due to the difference of the theoretical number of virtual tags produced by restriction digestion. The number of virtual tags in our analysis (approximately 394,000 virtual tags in the range of 30 to 60 bp) was less than that of DK (approximately 731,000 tags) [14]. Thus, while the current pilot study demonstrates the feasibility of using DGS to estimate copy number using a simplified tag preparation method, additional studies are needed, using different or combinations of restriction enzymes to produce more short tags, to improve the resolution of DGS. Second, DGS method has several limitations involved in labor, cost, and amount of material: (a) this method needs the generation of two rounds of plasmid libraries and the propagation of plasmid libraries, (b) this method costs higher than microarray platform and DK, (c) a large amount of starting material DNA is required.
###end p 68
###begin p 69
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1291 1293 1291 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1860 1862 1860 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1863 1865 1863 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1424 1429 <span type="species:ncbi:9606">human</span>
Recently, the use of single nucleotide polymorphism (SNP) arrays for the detection of allele-specific copy-number alterations at high resolution using 906,600 SNP probes has been reported [32]. Because DGS and DK do not rely on pre-designed probes, they are "open" platform techniques. For example, DK could be used to explore exogenous pathogenic DNA in infectious or neoplastic states [14]. However, tag-counting methods, including DGS and DK, have similar limitations. First, they generally do not estimate allele-specific copy number, which SNP array analysis does. Second, the number of sequence reads, which is to say, the depth of sequencing, affects the sensitivity and the resolution of tag density profiles. The results of simulated DGS indicated that DGS using deep sequencing will have a higher level of sensitivity in detecting subtle copy-number alterations. However, even in reports of successful DK [14-17], the depth of sequencing was less than 0.3 (when the theoretical number of unique virtual tags was defined as 1.0), partly due to practical limitations, such as the low through-put rate and labor intensive methods required when using standard sequencers [33]. In the next step of improving DGS, DGS should be combined with the next-generation sequencing technologies [34]. The recent introduction of instruments capable of sequence millions of nucleotides in a single run is changing the landscape of human genetics. By applying next-generation sequencing technologies to DGS, it should be possible to simplify the protocol and improve efficiency and resolution by bypassing the multi-step process of tag concatemerization, as well as conserve starting genomic DNA. With some next-generation sequencers, tag preparation by restriction digestion might generate more reproducible DNA fragmentation than current random-shearing approaches [35,36].
###end p 69
###begin p 70
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Gene amplification of KRAS with or without mutation has been described in a limited number of cases, including lung, gastric, pancreatic and rectal cancers [37-40]. More recently, aCGH analysis of various primary tumors, including lung, colorectal, pancreatic and gastric cancers, gliomas and testicular germ cell tumors, also detected amplification of chromosome 12p [41-46]. In this report, we provided evidence that, while rare in colon and pancreatic cancers, the incidence of KRAS gene amplification (greater than 4-fold) is increased in gastric cancer, and is responsible for KRAS activation.
###end p 70
###begin p 71
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 721 726 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1013 1017 1013 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1092 1097 1092 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Using MKN1 cells as a model system, we investigated the mechanism by which KRAS amplification contributes to the growth of primary gastric cancers that lack mutations in KRAS. Immunoblot analysis and knock-down of KRAS in cells provided evidence that KRAS gene amplification results in KRAS activation in the absence of mutation. To our knowledge, this is the first report to demonstrate a potential relationship between gene amplification of endogenous wild-type KRAS, activation of KRAS signaling pathways, and cell growth in gastric cancer. In general, less than 10% of wild-type and over 50% of mutant RAS is in the GTP-bound state in cells [47,48]. Therefore, it is likely that amplification of endogenous wild-type KRAS coupled overexpression in the MKN1 cells induces a biological effect that is similar to the effect of single-mutant alleles of KRAS. We also found that while serum stimulation induced the activation of overexpressed KRAS and p44/42 in MKN1 cells, in cells that harbored amplified mutant KRAS, KRAS and p44/42 were constitutively activated. Thus, amplified wild-type KRAS might provide a growth advantage to cancer cells, not only by upregulating the basal cell growth, but also by conferring adaptability to changes in the environment, such as availability of growth factors and nutrients. Further studies will be needed to investigate potential functional connections for these correlations.
###end p 71
###begin p 72
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 888 893 888 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1108 1113 1108 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 1060 1067 <span type="species:ncbi:9606">patient</span>
The KRAS gene status of tumors is currently of great interest, because KRAS mutations are linked to the response to anti-epidermal growth factor receptor (EGFR) therapies. Panitumumab and cetuximab are antibody-based drugs that inhibit EGFR, and are currently used in the treatment of colorectal cancer [49]. However, several groups have reported that KRAS mutations are significantly associated with lack of response to cetuximab or panitumumab in patients with advanced, chemotherapy-refractive colorectal cancer [50,51]. In gastric cancer, EGFR is a promising target since it is frequently overexpressed [52,53], and clinical trials of cetuximab in the treatment of gastric cancer are ongoing [54,55]. Our results showing that overexpressed wild-type KRAS is involved in the activation of downstream signaling pathways that govern cell proliferation indicate that the amplification of KRAS might be of clinical significance in predicting response to cetuximab or to panitumumab in gastric cancer. Prospective studies are needed to determine the efficacy of patient-specific EGFR-targeted therapy based on KRAS amplification and mutation status.
###end p 72
###begin title 73
Conclusion
###end title 73
###begin p 74
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
We demonstrated that DGS is an efficient method of identifying DNA copy-number alterations. Using DGS, we investigated the role of KRAS gene amplification in the overactivation of KRAS in gastric cancer. Future studies using a larger cohort of gastric cancer specimens are needed to elucidate the clinical, diagnostic and therapeutic significance of KRAS amplification and overexpression.
###end p 74
###begin title 75
Competing interests
###end title 75
###begin p 76
The authors declare that they have no competing interests.
###end p 76
###begin title 77
Authors' contributions
###end title 77
###begin p 78
###xml 127 137 127 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 434 444 434 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
HM performed molecular biological experiments including DGS, and wrote Perl scripts and the paper. FA, HA, RM and HT performed in silico genome analyses and constructed the tag database. YS and MI performed real-time PCR. LK performed Southern blotting. MT and HS extracted genomic DNA and performed sequencing. KY provided gastric cancer cell lines. MF, MH and MK provided primary samples and clinico-pathological data. SVS designed in silico DGS simulation and performed statistical analyses. KI, YS and TT conceived, coordinated the study and revised the paper. All authors read and approved the final manuscript.
###end p 78
###begin title 79
Pre-publication history
###end title 79
###begin p 80
The pre-publication history for this paper can be accessed here:
###end p 80
###begin p 81

###end p 81
###begin title 82
Supplementary Material
###end title 82
###begin title 83
Additional file 1
###end title 83
###begin p 84
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell lines used in this study.</bold>
Cell lines used in this study.
###end p 84
###begin p 85
Click here for file
###end p 85
###begin title 86
Additional file 2
###end title 86
###begin p 87
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Clinicopathological features of primary gastric carcinomas with or without <italic>KRAS </italic>amplification.</bold>
Clinicopathological features of primary gastric carcinomas with or without KRAS amplification.
###end p 87
###begin p 88
Click here for file
###end p 88
###begin title 89
Additional file 3
###end title 89
###begin p 90
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional Methods</bold>
Additional Methods
###end p 90
###begin p 91
Characterization of virtual tags and construction of virtual tag database 
###end p 91
###begin p 92
###xml 15 24 15 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
DGS simulation in silico
###end p 92
###begin p 93
DGS: preparation of real tag library, tag sequencing and tag density analysis
###end p 93
###begin p 94
Southern blot analysis
###end p 94
###begin p 95
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
Quantitative evaluation of mutant alleles of KRAS miR RT-PCR.
###end p 95
###begin p 96
Click here for file
###end p 96
###begin title 97
Additional file 4
###end title 97
###begin p 98
Primers for genomic qPCR.
###end p 98
###begin p 99
Click here for file
###end p 99
###begin title 100
Additional file 5
###end title 100
###begin p 101
Gene Expression Assay number and primer/probe sequences for qRT-PCR.
###end p 101
###begin p 102
Click here for file
###end p 102
###begin title 103
Additional file 6
###end title 103
###begin p 104
Primers for mutational analysis.
###end p 104
###begin p 105
Click here for file
###end p 105
###begin title 106
Additional file 7
###end title 106
###begin p 107
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characteristics of <italic>Mbo</italic>I virtual tags</bold>
###xml 39 40 39 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 54 55 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 86 89 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 250 251 250 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 324 327 324 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d-f</bold>
###xml 413 414 413 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 447 448 447 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 486 487 486 487 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 616 617 616 617 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
Characteristics of MboI virtual tags. (a) Repeat and (b) Uniqueness classification of MboI virtual tags. The actual number of MboI virtual tags (left) and the corresponding proportion (right) of tags of each length (from 20 bp to 130 bp) are shown. (c) Summary of the Repeat/Uniqueness classification of MboI virtual tags. (d-f) Frequency of intervals between two unique virtual tags in the range of 30 to 60 bp (d), in the range of 70 to 100 bp (e), and in the range of 100 to 130 bp (f). The interval frequency, in 200 bp, for each range is plotted. Corresponding cumulative frequency is also shown in each plot. (g) Chromosomal distribution of unique virtual tags. The actual number of unique virtual tags and the corresponding proportion in each chromosome are shown.
###end p 107
###begin p 108
Click here for file
###end p 108
###begin title 109
Additional file 8
###end title 109
###begin p 110
Theoretical detection of copy number alteration by DGS.
###end p 110
###begin p 111
Click here for file
###end p 111
###begin title 112
Additional file 9
###end title 112
###begin p 113
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genome regions with copy number alterations in HSC45 cells, as detected by DGS</bold>
###xml 81 84 81 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;d</bold>
###xml 127 128 127 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 144 145 144 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CACNA1C</italic>
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 238 239 238 239 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 303 304 303 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 594 595 594 595 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 628 632 628 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 787 790 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 881 885 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 891 894 891 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
Genome regions with copy number alterations in HSC45 cells, as detected by DGS. (a-d) DGS identified amplifications at 8q24.2 (a) and 12p13.33 (b), which contain MYC and CACNA1C, respectively; a deletion at 9p21.3, which contains CDKN2A (c); and a copy number decrease at the long arm of chromosome 18 (d) in HSC45 cells. The upper panel of each figure shows the tag density ratio, the maps of real and virtual tags, and refseq genes. The lower panel shows genomic qPCR analysis of copy number. DNA copy number was normalized to Line-1, a repetitive element, and normal diploid leukocyte DNA. (e) Gene amplification of KRAS and MYC in HSC45 gastric cancer cells was confirmed by Southern blot analysis. The indicated amounts of genomic DNA from HSC45 and HEK293 cells were digested with MspI, separated by 0.8% agarose gel electrophoresis, and then analyzed by Southern blot using KRAS- and MYC-specific probes.
###end p 113
###begin p 114
Click here for file
###end p 114
###begin title 115
Additional file 10
###end title 115
###begin p 116
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 145 0 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amplification of the chromosomal region from 12p12.1 to 12p11.22, which includes the <italic>KRAS </italic>locus, was detected in MKN1 gastric cancer cells by DGS</bold>
###xml 148 149 148 149 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 262 263 262 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 577 582 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Amplification of the chromosomal region from 12p12.1 to 12p11.22, which includes the KRAS locus, was detected in MKN1 gastric cancer cells by DGS. (a) Whole-genome profile of the tag density ratio (determined using a window of 1000 virtual tags) of MKN1 cells. (b) Whole-chromosome view of the tag density ratio (using a window of 3000 virtual tags) of chromosome 12. Unique real tags are indicated as black vertical bars in squish mode, and unique virtual tags are indicated in blue (60 bp or shorter) or light blue (longer than 60 bp) bars in dense mode. The position of the KRAS locus is indicated at the bottom.
###end p 116
###begin p 117
Click here for file
###end p 117
###begin title 118
Additional file 11
###end title 118
###begin p 119
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Missense mutations of <italic>KRAS </italic>and <italic>PIK3CA</italic>, and amplified mutant alleles of <italic>KRAS </italic>in gastric cancer cells</bold>
###xml 102 103 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 394 395 394 395 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 425 430 425 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 491 496 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 711 716 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 874 875 872 873 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 903 910 901 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Missense mutations of KRAS and PIK3CA, and amplified mutant alleles of KRAS in gastric cancer cells. (a) Mutation of codon 12 of KRAS in HSC45, SH101P4 and AGS cells. Sequence chromatograms of KRAS missense mutations were generated by nucleotide sequencing of PCR products directly, or sequencing of PCR clones. Mutated codons are underlined. Representative results from PCR clones are shown. (b) Amplified mutant alleles of KRAS in HSC45 and SH101P4 cells. The allelic proportion of mutant KRAS (G12V, ggt-->gTt) was analyzed by duplex real-time PCR using mutant (gTt) and wild-type (ggt) allele-specific probes labeled by FAM and VIC, respectively. Serial dilutions of vectors for mutant (M) or wild-type (W) KRAS were mixed at the indicated ratios, and then used as standards. The fluorescence intensity of the two different dyes is presented as a two-dimensional plot. (c) Mutations of codon 545 of PIK3CA in MKN1 and AGS cells. Mutated codons are underlined. Representative results from cloned PCR products are shown.
###end p 119
###begin p 120
Click here for file
###end p 120
###begin title 121
Additional file 12
###end title 121
###begin p 122
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of the microRNAs let7-c and let7-g in gastric cancer cells that overexpress KRAS</bold>
Expression of the microRNAs let7-c and let7-g in gastric cancer cells that overexpress KRAS. Semiquantitative RT-PCR analysis of microRNAs was carried out using small RNAs derived from the indicated cell lines. The expression levels of let7-a, U6 and hsa-miR-24 were analyzed as controls. Reaction products were analyzed by 3.0% Nusieve agarose gel electrophoresis.
###end p 122
###begin p 123
Click here for file
###end p 123
###begin title 124
Additional file 13
###end title 124
###begin p 125
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene expression in siRNA knock-down cells</bold>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRMP</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASC1</italic>
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5</italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 273 274 273 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRMP</italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASC1 </italic>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYRM5 </italic>
###xml 303 304 303 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
Gene expression in siRNA knock-down cells. Gastric cancer cell lines were transfected with siRNAs for KRAS, LRMP, CASC1, LYRM5, or a universal non-targeting siRNA as a negative control. Cells were cultured for 48 h and then total RNA was isolated. mRNA expression of KRAS (a) and LRMP, CASC1 and LYRM5 (b) in each cell line was determined by qRT-PCR. The expression of each gene was normalized to that of GAPDH and normal stomach mRNA. Non, nontransfected cells. Data represents the means and SD of three independent experiments.
###end p 125
###begin p 126
Click here for file
###end p 126
###begin title 127
Acknowledgements
###end title 127
###begin p 128
We thank Drs. Sam Thiagalingam and Joseph F. Costello for critical reading of this manuscript. We also thank Tomoko Takahashi, Miho Higuchi, Reia Hosokawa, Tetsuya Fujii, Masami Ashida, Mutsumi Toyota and Kyoko Fujii for their excellent technical support. Grant support: Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology (MT, YS, KI and TT) and Industrial Technology Research Grant Program from New Energy and Industrial Technology Development Organization of Japan (HM).
###end p 128
###begin article-title 129
Cancer burden in the year 2000. The global picture
###end article-title 129
###begin article-title 130
Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis
###end article-title 130
###begin article-title 131
Hyperactive Ras in developmental disorders and cancer
###end article-title 131
###begin article-title 132
###xml 35 40 <span type="species:ncbi:9606">human</span>
Activation of c-K-ras mutations in human gastrointestinal tumors
###end article-title 132
###begin article-title 133
BRAF and KRAS mutations in stomach cancer
###end article-title 133
###begin article-title 134
###xml 139 157 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus
###end article-title 134
###begin article-title 135
Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach
###end article-title 135
###begin article-title 136
RAS is regulated by the let-7 microRNA family
###end article-title 136
###begin article-title 137
Gene amplification in cancer
###end article-title 137
###begin article-title 138
Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research
###end article-title 138
###begin article-title 139
Array comparative genomic hybridization and its applications in cancer
###end article-title 139
###begin article-title 140
Design optimization methods for genomic DNA tiling arrays
###end article-title 140
###begin article-title 141
Optimized design and assessment of whole genome tiling arrays
###end article-title 141
###begin article-title 142
Digital karyotyping
###end article-title 142
###begin article-title 143
###xml 145 153 <span type="species:ncbi:9606">patients</span>
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients
###end article-title 143
###begin article-title 144
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
###end article-title 144
###begin article-title 145
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid
###end article-title 145
###begin article-title 146
Homozygous deletion of MKK4 in ovarian serous carcinoma
###end article-title 146
###begin article-title 147
Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma
###end article-title 147
###begin article-title 148
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 130 139 <span type="species:ncbi:10090">nude mice</span>
Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice
###end article-title 148
###begin article-title 149
The Two Histological Main Types Of Gastric Carcinoma: Diffuse And So-Called Intestinal-Type Carcinoma. An Attempt At A Histo-Clinical Classification
###end article-title 149
###begin article-title 150
UCSC genome browser (Mar. 2006 freeze, hg18)
###end article-title 150
###begin article-title 151
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human genome browser at UCSC
###end article-title 151
###begin article-title 152
The UCSC Genome Browser Database: 2008 update
###end article-title 152
###begin article-title 153
Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes
###end article-title 153
###begin article-title 154
Identification of the interleukin 4 receptor alpha gene as a direct target for p73
###end article-title 154
###begin article-title 155
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer
###end article-title 155
###begin article-title 156
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers
###end article-title 156
###begin article-title 157
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice
###end article-title 157
###begin article-title 158
ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation
###end article-title 158
###begin article-title 159
Integrated detection and population-genetic analysis of SNPs and copy number variation
###end article-title 159
###begin article-title 160
Digital karyotyping
###end article-title 160
###begin article-title 161
Genomics: the personal side of genomics
###end article-title 161
###begin article-title 162
Genome sequencing in microfabricated high-density picolitre reactors
###end article-title 162
###begin article-title 163
Accurate multiplex polony sequencing of an evolved bacterial genome
###end article-title 163
###begin article-title 164
ras gene Amplification and malignant transformation
###end article-title 164
###begin article-title 165
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene
###end article-title 165
###begin article-title 166
Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes
###end article-title 166
###begin article-title 167
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung
###end article-title 167
###begin article-title 168
Characterizing the cancer genome in lung adenocarcinoma
###end article-title 168
###begin article-title 169
Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types
###end article-title 169
###begin article-title 170
High-resolution characterization of the pancreatic adenocarcinoma genome
###end article-title 170
###begin article-title 171
Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours
###end article-title 171
###begin article-title 172
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations
###end article-title 172
###begin article-title 173
###xml 49 54 <span type="species:ncbi:9606">human</span>
Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis
###end article-title 173
###begin article-title 174
###xml 71 76 <span type="species:ncbi:9606">human</span>
Biochemical characterization of a novel KRAS insertion mutation from a human leukemia
###end article-title 174
###begin article-title 175
Regulation of ras signaling dynamics by Sos-mediated positive feedback
###end article-title 175
###begin article-title 176
EGFR antagonists in cancer treatment
###end article-title 176
###begin article-title 177
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
###end article-title 177
###begin article-title 178
###xml 54 62 <span type="species:ncbi:9606">patients</span>
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
###end article-title 178
###begin article-title 179
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system
###end article-title 179
###begin article-title 180
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
###end article-title 180
###begin article-title 181
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
###end article-title 181
###begin article-title 182
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-2)
###end article-title 182

